MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Alnylam Pharmaceuticals EV/EBITDA Ratio 2011-2026 | ALNY
Annual EV/EBITDA Ratio Alnylam Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -31.5 | -22.5 | -13.6 | -9.69 | -23.2 | -7.6 | -20.3 | -40 | -63.3 | -21 | -8.11 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -7.6 | -63.3 | -23.7 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
-6.39 | $ 20.7 | - | $ 2.61 B | USA |
 |
Aptorum Group Limited
APM
|
29.4 | $ 0.84 | - | $ 4.58 M | China |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-8.03 | $ 166.38 | - | $ 8.28 B | USA |
 |
AbCellera Biologics
ABCL
|
9.24 | $ 3.82 | - | $ 1.14 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Corcept Therapeutics Incorporated
CORT
|
17.3 | $ 35.97 | - | $ 3.74 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
7.16 | $ 23.88 | - | $ 2.92 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-0.248 | $ 8.35 | - | $ 36.1 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
0.244 | $ 17.89 | - | $ 859 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Champions Oncology
CSBR
|
77 | $ 6.07 | 2.71 % | $ 82.9 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-2.05 | $ 0.72 | - | $ 4.84 M | USA |
 |
Daré Bioscience
DARE
|
-2.25 | $ 1.61 | - | $ 13.7 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-0.266 | $ 23.25 | - | $ 2.26 B | France |
 |
ARCA biopharma
ABIO
|
1.84 | - | 1052.0 % | $ 415 M | USA |
 |
Capricor Therapeutics
CAPR
|
-2.14 | $ 26.86 | - | $ 719 M | USA |
 |
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-5.5 | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | USA |
 |
Edesa Biotech
EDSA
|
-1.27 | $ 2.28 | - | $ 7.29 M | USA |
 |
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M | Canada |
 |
Eton Pharmaceuticals
ETON
|
-53 | $ 18.15 | - | $ 465 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
0.832 | $ 8.22 | -3.18 % | $ 218 M | USA |
|
Foghorn Therapeutics
FHTX
|
-11.7 | $ 5.76 | - | $ 316 M | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Amicus Therapeutics
FOLD
|
-14 | $ 14.36 | - | $ 4.43 B | USA |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
-100 | $ 1.02 | - | $ 74.9 M | USA |
 |
Galectin Therapeutics
GALT
|
-1.92 | $ 3.06 | 2.68 % | $ 191 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
Gilead Sciences
GILD
|
8.3 | $ 150.03 | - | $ 187 B | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-8.96 | $ 3.34 | - | $ 1.2 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M |  Israel |
 |
Galapagos NV
GLPG
|
-26.5 | $ 34.09 | - | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-47.7 | $ 27.39 | - | $ 356 M | USA |
|
Galecto
GLTO
|
-0.349 | $ 30.05 | - | $ 798 M |  Danmark |
 |
Genmab A/S
GMAB
|
2.7 | $ 29.65 | - | $ 18.9 B | Danmark |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-5.08 | $ 29.2 | - | $ 1.69 B | USA |
 |
GeoVax Labs
GOVX
|
-0.113 | $ 1.56 | -2.5 % | $ 2.83 M | USA |